<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl. 2012 Dec;2(5):337-414. [453 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004 May;43(5 Suppl 1):S1-290.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Chronic kidney disease, unspecified  (585.9); Complications affecting other specified body systems, not elsewhere classified, hypertension  (997.91); Diabetes with renal manifestations, type I [juvenile type], not stated as uncontrolled  (250.41); Diabetes with renal manifestations, type II or unspecified type, not stated as uncontrolled  (250.40)"/><FieldValue Value="MSH: Adrenergic alpha-Antagonists ; Adrenergic beta-Antagonists ; Alcohol Drinking ; Angiotensin II Type 1 Receptor Blockers ; Angiotensin-Converting Enzyme Inhibitors ; Antihypertensive Agents ; Calcium Channel Blockers ; Diabetic Nephropathies ; Diet, Sodium-Restricted ; Diuretics ; Exercise ; Hypertension ; Kidney Diseases ; Kidney Transplantation ; Life Style ; Renal Insufficiency, Chronic ; Vasodilator Agents "/><FieldValue Value="MTH: Adrenergic alpha-Antagonists ; Adrenergic beta-Antagonists ; Alcohol consumption ; Aldosterone Antagonists ; Angiotensin II Type 1 Receptor Blockers ; Angiotensin-Converting Enzyme Inhibitors ; Antihypertensive Agents ; Calcium Channel Blockers ; Chronic Kidney Diseases ; Chronic Kidney Insufficiency ; Diabetic Nephropathy ; Exercise ; Hypertensive disease ; Kidney Diseases ; Kidney Transplantation ; Life Style ; Low sodium diet ; Thiazide Diuretics ; Vasodilator Agents ; Weight maintenance regimen finding "/><FieldValue Value="PDQ: kidney transplantation "/><FieldValue Value="SNOMEDCT_US: Alcohol intake  (160573003); Aldosterone antagonist  (346312000); Aldosterone antagonist  (372603003); Alpha-adrenergic blocking agent  (373275009); Alpha-adrenergic blocking agent  (67440007); Angiotensin-converting enzyme inhibitor agent  (372733002); Angiotensin-converting enzyme inhibitor agent  (41549009); beta-Blocking agent  (33252009); beta-Blocking agent  (373254001); Calcium channel blocker  (373304005); Calcium channel blocker  (48698004); Chronic renal impairment  (236425005); Diabetic renal disease  (127013003); Diuretic  (30492008); Diuretic  (372695000); Exercise  (183301007); Exercise  (256235009); Exercise  (61686008); Hypertension clinical management plan  (412779008); Hypertensive disorder  (38341003); Hypotensive agent  (1182007); Hypotensive agent  (372586001); Kidney disease  (90708001); Life style  (134436002); Life style  (60134006); Low sodium diet  (386619000); Low sodium diet  (437421000124105); Target diastolic blood pressure  (315613000); Target systolic blood pressure  (315612005); Thiazide diuretic  (372747003); Thiazide diuretic  (45518007); Transplant of kidney  (70536003); Vasodilating agent  (372787008); Vasodilating agent  (58944007); Weight maintenance regimen  (33861001)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;Hypertension&lt;/li&gt;&#xA;    &lt;li&gt;Chronic kidney disease, including:&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;        &lt;li&gt;Diabetic kidney disease&lt;/li&gt;&#xA;        &lt;li&gt;Nondiabetic kidney diseases &lt;/li&gt;&#xA;        &lt;li&gt;Kidney disease in the kidney transplant recipient&lt;/li&gt;&#xA;    &lt;/ul&gt;&#xA;    &lt;/li&gt;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Management" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Endocrinology" /><FieldValue Value="Family Practice" /><FieldValue Value="Geriatrics" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Nephrology" /><FieldValue Value="Pediatrics" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Allied Health Personnel" /><FieldValue Value="Dietitians" /><FieldValue Value="Health Care Providers" /><FieldValue Value="Nurses" /><FieldValue Value="Pharmacists" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /><FieldValue Value="Social Workers" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;To provide advice on the management of blood pressure (BP) in patients with non&amp;ndash;dialysis-dependent chronic kidney disease (CKD ND) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To assist the practitioner caring for patients with non-dialysis CKD and hypertension and to prevent deaths, cardiovascular disease (CVD) events, and progression to kidney failure while optimizing patients' quality of life &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To update the National Kidney Foundation's (NKF) &lt;em&gt;Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease&lt;/em&gt;, which was based on evidence collected up to 2001, by incorporating the evidence gathered since then &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Adults with non-dialysis-dependent chronic kidney disease (CKD ND) without diabetes mellitus &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Adults with CKD ND with diabetes mellitus &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Adults with CKD ND who have received a kidney transplant (CKD T) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Children with CKD ND &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Elderly with CKD ND &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Establishment of individualized target blood pressure (BP) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Inquiring about dizziness and postural hypotension when BP-lowering drugs are used &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Lifestyle modification&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Achieving/maintaining healthy body weight &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Lowering salt intake &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Exercise program &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Limiting alcohol intake &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Use of BP-lowering drugs:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Angiotensin converting enzyme inhibitors (ACE-Is) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Angiotensin receptor blockers (ARBs) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Other BP-lowering drugs or combinations (aldosterone antagonists, beta-blockers, calcium-channel blockers, diuretics) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Blood pressure management in patients without diabetes mellitus &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Blood pressure management in patients with diabetes mellitus &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Blood pressure management in kidney transplant recipients &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Blood pressure management in children &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Blood pressure management in the elderly &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Mortality &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cardiovascular mortality &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cardiovascular events &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Kidney failure &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Composite including clinical events &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Doubling of serum creatinine (SCr) or halving of glomerular filtration rate (GFR) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Proteinuria (categorical) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Kidney function (continuous) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Urine protein level (continuous) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Adverse events: drug discontinuation or dose decrease, hyperkalemia, early rise of SCr or decrease of GFR &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Work Group sought to build on the evidence base from the previous &lt;em&gt;KDOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease&lt;/em&gt;. As the first search for the Kidney Disease Outcomes Quality Initiative (KDOQI) guideline was conducted in July 2002, the search for the current KDIGO Guideline included publications since January 2002. Search strategies were developed by the Evidence Review Team (ERT) with input from the Work Group. The text words or medical subject headings (MeSH) that were included are provided in Supplementary Appendix 1 online (see the &quot;Availability of Companion Documents&quot; field). Non-human studies and those focusing on dialysis, pregnancy, neonates, malignant hypertension, acute kidney injury, or drug pharmacology were excluded.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MEDLINE, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews were searched by the ERT to capture all randomized controlled trials (RCTs) on the use of blood pressure (BP)-lowering agents in chronic kidney disease (CKD). The first search was conducted in November 2009 and was subsequently updated in April and August of 2010; the final update was done in January 2011. Additional focused searches were conducted to identify RCTs evaluating lifestyle interventions of salt restriction, weight loss, and diet and exercise in chronic kidney disease (CKD) and to look for reviews of adverse effects of anti-hypertensive agents. The ERT relied on Work Group members to identify large, general population RCTs reporting on subgroup analyses based on CKD, glomerular filtration rate (GFR), or proteinuria status. Additional pertinent articles were added from the reference lists of Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) and relevant meta-analyses and systematic reviews (see Table 7 in the original guideline document). The search yield was also supplemented by articles provided by Work Group members through February 2012.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A total of 10,657 citations were initially screened. Journal articles reporting original data, meta-analyses, and systematic reviews were selected for evidence review. Editorials, letters, abstracts, unpublished reports, and articles published in non&amp;ndash;peer-reviewed journals were not included. The Work Group also decided to exclude publications from journal supplements because of potential differences in the process of how they get solicited, selected, reviewed, and edited compared to peer-reviewed publications. &lt;em&gt;Post hoc&lt;/em&gt; analyses were also excluded, however, after discussion with the Work Group, it was decided that exception would be made for post-trial observational follow-up reports from RCTs looking at BP targets as BP interventions may take longer time to influence outcomes. These studies were downgraded one level to designate that they are of lesser quality than the original RCT.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Limitations of Approach&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Although the literature searches were intended to be comprehensive, they were not exhaustive. MEDLINE was the only database searched. Hand searches of journals were not performed, and review articles and textbook chapters were not systematically searched. However, important studies known to domain experts that were missed by the electronic literature searches were added to retrieved articles and reviewed by the Work Group.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A total of 10,657 citations were initially screened, and 247 articles were retrieved. Data extraction was performed on 55 studies. The overall search yield along with the number of abstracts identified and articles reviewed for each topic are presented in Table 8 of the original guideline document.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Grading of Recommendations Assessment, Development and Evaluation (GRADE) System for Grading Quality of Evidence for an Outcome&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Grading of Recommendations Assessment, Development and Evaluation (GRADE) System for Grading Quality of Evidence for an Outcome&quot;&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; colspan=&quot;2&quot;&gt;Step 1: Starting Grade for Quality of Evidence Based on Study Design&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Randomized trials&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;High&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Observational study&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Low&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Any other evidence&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Very low&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; colspan=&quot;2&quot;&gt;Step 2: Reduce Grade&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Study quality&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;-1 level if serious limitations&lt;br /&gt;&#xD;&#xA;            -2 levels if very serious limitations&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Consistency&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;-1 level if important inconsistency&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Directness&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;-1 level if some uncertainty&lt;br /&gt;&#xD;&#xA;            -2 levels if major uncertainty&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Other&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;-1 level if sparse or imprecise data&lt;sup&gt;c&lt;/sup&gt;&lt;br /&gt;&#xD;&#xA;            -1 level if high probability of reporting bias&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; colspan=&quot;2&quot;&gt;Step 3: Raise Grade&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Strength of association&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;+1 level if strong,&lt;sup&gt;a&lt;/sup&gt; no plausible confounders&lt;br /&gt;&#xD;&#xA;            +2 levels if very strong,&lt;sup&gt;b&lt;/sup&gt; no major threats to validity&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Other&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;+1 level if evidence of a dose&amp;ndash;response gradient&lt;br /&gt;&#xD;&#xA;            +1 level if all residual plausible confounders would have reduced the observed effect&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; colspan=&quot;2&quot;&gt;Final Grade for Quality of Evidence and Definition&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;High&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Further research is unlikely to change confidence in the estimate of the effect&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Moderate&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Further research is likely to have an important impact on confidence in the estimate of effect, and may change the estimate&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Low&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Further research is very likely to have an important impact on confidence in the estimate, and may change the estimate&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Very low&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Any estimate of effect is very uncertain&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;a&lt;/sup&gt;Strong evidence of association is defined as 'significant relative risk (RR) of &amp;gt;2 (&amp;lt;0.5)' based on consistent evidence from two or more observational studies, with no plausible confounders.&lt;br /&gt;&#xD;&#xA;&lt;sup&gt;b&lt;/sup&gt;Very strong evidence of association is defined as 'significant RR of &amp;gt;5 (&amp;lt;0.2)' based on direct evidence with no major threats to validity.&lt;br /&gt;&#xD;&#xA;&lt;sup&gt;c&lt;/sup&gt;Sparse if there is only one study or if total N &amp;lt;100. Imprecise if there is a low event rate (0 or 1 event) in either arm or confidence interval spanning a range &amp;lt;0.5 to &amp;gt;2.0.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;Adapted by permission from Macmillan Publishers Ltd, &lt;em&gt;Kidney International&lt;/em&gt;. Uhlig et al. Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 70: 2058&amp;ndash;2065.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Final Grade for Overall Quality of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Final Grade for Overall Quality of Evidence&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Grade&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Quality of Evidence&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Meaning&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;A&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;High&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The Work Group is confident that the true effect lies close to that of the estimate of the effect.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;B&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;Moderate&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;C&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;Low&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The true effect may be substantially different from the estimate of the effect.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;D&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;Very Low&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The estimate of effect is very uncertain, and often will be far from the truth.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review with Evidence Tables" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Data Extraction&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Data extraction was done by the Evidence Review Team (ERT). The ERT, in consultation with the Work Group, designed forms to capture data on design, methodology, sample characteristics, interventions, comparators, outcomes, results, and limitations of individual studies. Methodology and outcomes were also systematically graded (see the section on grading below) and recorded during the data extraction process.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Summary Tables&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Summary tables were developed for each comparison of interest (see Table 9 in the original guideline document). Studies included in the evidence base for the &lt;em&gt;KDOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease&lt;/em&gt; were also incorporated if they fulfilled the inclusion criteria for the current Kidney Disease: Improving Global Outcomes (KDIGO) Guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Summary tables contain outcomes of interest, relevant population characteristics, description of intervention and comparator, results, and quality grading for each outcome. Categorical and continuous outcomes were summarized separately. Studies done exclusively in patients of a single race or ethnicity and studies reporting effect modifications by baseline urine protein level were annotated. Studies were also categorized by baseline proteinuria status in summary tables for the chronic kidney disease (CKD) with diabetes mellitus topic.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For studies not exclusively examining CKD population, only those reporting analysis by CKD subgroups were tabulated. Studies including both diabetes mellitus and non-diabetes mellitus populations were included in summary tables for the CKD without diabetes mellitus topic unless results of subgroup analysis by diabetes mellitus status was provided.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Work Group members proofed all summary table data and quality assessments. Summary tables are available at &lt;a href=&quot;http://www.kdigo.org&quot; title=&quot;KDIGO Web site&quot;&gt;www.kdigo.org&lt;/a&gt; (see the &quot;Availability of Companion Documents&quot; field).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Evidence Profiles&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Evidence profiles were constructed to assess the quality and record quality grades and descriptions of effect for each outcome across studies, as well as the quality of overall evidence and description of net benefits or harms of the intervention or comparator across all outcomes. These profiles aim to make the evidence synthesis process transparent. Decisions in the evidence profiles were based on data from the primary studies listed in corresponding summary tables and on judgments of the ERT and the Work Group. When the body of evidence for a particular comparison of interest consisted of only one study, the summary table provided the final level of synthesis and an evidence profile was not generated. Evidence profiles were also not created for studies that did not exclusively examine CKD population. Each evidence profile was initially constructed by the ERT and then reviewed, edited, and approved by the Work Group. The work products created by the ERT for summarizing the evidence base are listed in Table 9 in the original guideline document.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grading of Quality of Evidence for Outcomes of Individual Studies&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Methodological Quality&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Methodological quality (internal validity) refers to the design, conduct, and reporting of outcomes of a clinical study. A previously devised three-level classification system for quality assessment was used to grade the overall study quality and quality of all relevant outcomes in the study (see Table 10 in the original guideline document). Variations of this system have been used in most Kidney Disease Outcomes Quality Initiative (KDOQI) and all KDIGO guidelines and have been recommended for the US Agency for Healthcare Research and Quality Evidence-based Practice Center program.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Each study was given an overall quality grade based on its design, methodology (randomization, allocation, blinding, definition of outcomes, appropriate use of statistical methods, etc.), conduct (dropout percentage, outcome assessment methodologies, etc.) and reporting (internal consistency, clarity, thoroughness and precision, etc.). Each reported outcome was then evaluated and given an individual grade depending on the quality of reporting and methodological issues specific to that outcome. However, the quality grade of an individual outcome could not exceed the quality grade for the overall study.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grading the Quality of Evidence and the Strength of a Guideline Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A structured approach, based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and facilitated by the use of evidence profiles was used to grade the quality of the overall evidence and the strength of recommendations. For each topic, the discussion on grading of the quality of the evidence was led by the ERT. The 'quality of a body of evidence' refers to the extent to which confidence in an estimate of effect is sufficient to support a particular recommendation.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Grading the Quality of Evidence for Each Outcome across Studies&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Following GRADE, the quality of a body of evidence pertaining to a particular outcome of interest was initially categorized on the basis of study design. For questions of interventions, the initial quality grade was 'High' if the body of evidence consisted of randomized controlled trials (RCTs), 'Low' if it consisted of observational studies, and 'Very Low' if it consisted of studies of other study designs. For questions of interventions, the Work Group decided to use only RCTs. The grade for the quality of evidence for each intervention&amp;ndash;outcome pair was then lowered if there were serious limitations to the methodological quality of the aggregate of studies, if there were important inconsistencies in the results across studies, if there was uncertainty about the directness of evidence including limited applicability of the findings to the population of interest, if the data were imprecise (a low event rate in either arm or a confidence interval [CI] spanning a range &amp;gt;1) or sparse (only 1 study or total N &amp;lt;500), or if there was thought to be a high likelihood of bias. The final grade for the quality of the evidence for an intervention&amp;ndash;outcome pair could be one of the following four grades: 'High', 'Moderate', 'Low' or 'Very Low' (see &quot;Rating Scheme for the Strength of the Evidence&quot; field).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Grading the Overall Quality of Evidence&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The quality of the overall body of evidence was then determined on the basis of the quality grades for all outcomes of interest, taking into account explicit judgments about the relative importance of each outcome. The resulting four final categories for the quality of overall evidence were: 'A', 'B', 'C', or 'D' (see the &quot;Rating Scheme for the Strength of the Evidence&quot; field).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;See the original guideline document for additional discussion of assessment of net health benefit across all important clinical outcomes, ungraded statements, and the format for guideline recommendations.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Overview of Process&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Work Group, Kidney Disease: Improving Global Outcomes (KDIGO) Co-Chairs, Evidence Review Team (ERT), and KDIGO support staff met for three 2-day meetings for training in the guideline development process, topic discussion, and consensus development.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Commissioning of Work Group and ERT&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The KDIGO Co-Chairs appointed the Work Group Co-Chairs, who then assembled the Work Group of domain experts, including individuals with expertise in internal medicine, adult and pediatric nephrology, cardiology, hypertension, pharmacology, epidemiology, and endocrinology. The Tufts Center for Kidney Disease Guideline Development and Implementation at Tufts Medical Center in Boston, Massachusetts, USA, was contracted to conduct systematic evidence review and provide expertise in guideline development methodology. The ERT consisted of physician&amp;ndash;methodologists with expertise in nephrology, a project coordinator and manager, and a research assistant. The ERT instructed and advised Work Group members in all steps of literature review, critical literature appraisal, and guideline development. The Work Group and the ERT collaborated closely throughout the project.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Defining Scope and Topics&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Work Group Co-Chairs first defined the overall scope and goals of the guideline and then drafted a preliminary list of topics and key clinical questions. The Work Group and ERT further developed and refined each topic and specified screening criteria, literature search strategies, and data extraction forms (see Table 5 in the original guideline document).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Given the lack of robust evidence, the Work Group decided not to make guideline recommendations for patients with kidney failure (CKD 5D). The Work Group decided instead to refer readers to the KDIGO Controversies Conference paper on this topic.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Establishing the Process for Guideline Development&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The ERT performed literature searches and organized abstract and article screening. The ERT also coordinated the methodological and analytical processes and defined and standardized the methodology for performing literature searches, data extraction, and summarizing the evidence. Throughout the project, the ERT offered suggestions for guideline development and led discussions on systematic review, literature searches, data extraction, assessment of quality and applicability of articles, evidence synthesis, grading of evidence and guideline recommendations, and consensus development. The Work Group took the primary role of writing the recommendation statements and rationale and retained final responsibility for their content.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Work Group Co-Chairs prepared the first draft of the scope of work document as a series of open-ended questions to be considered by Work Group members. At their first 2-day meeting, members added further questions until the initial working document included all topics of interest to the Work Group. The inclusive, combined set of questions formed the basis for the deliberation and discussion that followed. The Work Group strove to ensure that all topics deemed clinically relevant and worthy of review were identified and addressed.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Formulating Questions of Interest&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Questions of interest were formulated according to the PICODD (Population, Intervention, Comparator, Outcome, study Design and Duration of follow-up) criteria. Details of the criteria are presented in Table 5 in the original guideline document.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Ranking of Outcomes&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Work Group ranked outcomes of interest on the basis of their importance for informing clinical decision making (see Table 6 in the original guideline document). Doubling of serum creatinine (SCr) level or halving of glomerular filtration rate (GFR) was upgraded from 'high' to 'critical' importance in studies where the baseline GFR was &amp;lt; 60 ml/min/1.73 m&lt;sup&gt;2&lt;/sup&gt; (or the SCr was &amp;gt;2 mg/dl [&amp;gt;177&amp;micro;mol/l]), given the known adverse consequences of advanced CKD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grading the Quality of Evidence and the Strength of a Guideline Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A structured approach, based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and facilitated by the use of evidence profiles was used to grade the quality of the overall evidence and the strength of recommendations. For each topic, the discussion regarding the strength of the recommendations was led by the Work Group Co-Chairs.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The 'strength of a recommendation' indicates the extent to which one can be confident that adherence to the recommendation will do more good than harm.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Nomenclature and Description for Grading Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Nomenclature and Description for Grading Recommendations&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; colspan=&quot;3&quot;&gt;Implications&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Grade&lt;sup&gt;a&lt;/sup&gt;&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Patients&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Clinicians&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Policy&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;strong&gt;Level 1&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;            'The Work Group recommends'&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Most people in your situation would want the recommended course of action and only a small proportion would not.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Most patients should receive the recommended course of action.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The recommendation can be evaluated as a candidate for developing a policy or a performance measure.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;strong&gt;Level 2&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;            'The Work Group suggests'&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The majority of people in your situation would want the recommended course of action, but many would not.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Different choices will be appropriate for different patients. Each patient needs help to arrive at a management decision consistent with her or his values and preferences.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The recommendation is likely to require debate and involvement of stakeholders before policy can be determined.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;a&lt;/sup&gt;The additional category 'Not Graded' was used, typically, to provide guidance based on common sense or where the topic does not allow adequate application of evidence. The most common examples include recommendations regarding monitoring intervals, counseling, and referral to other clinical specialists. The ungraded recommendations are generally written as simple declarative statements, but are not meant to be interpreted as being stronger recommendations than Level 1 or 2 recommendations.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="Comparison with Guidelines from Other Groups" /><FieldValue Value="External Peer Review" /><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The guideline draft was sent for peer review to the Kidney Disease: Improving Global Outcomes (KDIGO) Board of Directors in December 2010 and for public review in July 2011.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Review of Guideline Development Process&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Several tools and checklists have been developed to assess the quality of the methodological process for guideline development. These include the Appraisal of Guidelines for Research and Evaluation (AGREE) criteria, the Conference on Guideline Standardization (COGS) checklist, and the Institute of Medicine's recent &lt;em&gt;Standards for Systematic Reviews&lt;/em&gt;, and &lt;em&gt;Clinical Practice Guidelines We Can Trust&lt;/em&gt;. Table 17 in the original guideline document and Supplementary Appendix 2 online (see the &quot;Availability of Companion Documents&quot; field) show, respectively, the COGS criteria and the Institute of Medicine standards, and how each one of them is addressed in this Guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Comparison with Other Guidelines&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Work group tabulated recommendations from other key English-language guidelines pertinent to the use of blood-pressure lowering agents in individuals with chronic kidney disease (CKD) (see Table 16 in the original guideline document). This served to inform topic selection and scope. Also, after recommendations had been drafted, the Work Group reviewed them in the context of the existing guideline recommendations to avoid unnecessary or unwarranted discrepancies.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Definitions of the strength of recommendation (&lt;strong&gt;Level 1, Level 2, or Not Graded&lt;/strong&gt;) and the quality of the supporting evidence (&lt;strong&gt;A-D&lt;/strong&gt;) are provided at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Lifestyle and Pharmacological Treatments for Lowering Blood Pressure in Chronic Kidney Disease (CKD) Non-dialysis-Dependent (ND) Patients&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;General Strategies&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Individualize blood pressure (BP) targets and agents according to age, co-existent cardiovascular disease and other co-morbidities, risk of progression of CKD, presence or absence of retinopathy (in CKD patients with diabetes) and tolerance of treatment. (&lt;strong&gt;Not Graded&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Inquire about postural dizziness and check for postural hypotension regularly when treating CKD patient's with BP-lowering drugs. (&lt;strong&gt;Not Graded&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Lifestyle Modification&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Encourage lifestyle modification in patients with CKD to lower BP and improve long term cardiovascular and other outcomes:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;The Work Group recommends achieving or maintaining a healthy weight (body mass index [BMI] 20 to 25). (&lt;strong&gt;1D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;The Work Group recommends lowering salt intake to &amp;lt;90 mmol (&amp;lt;2 g) per day of sodium (corresponding to 5 g of sodium chloride), unless contraindicated. (&lt;strong&gt;1C&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;The Work Group recommends undertaking an exercise program compatible with cardiovascular health and tolerance, aiming for at least 30 minutes 5 times per week. (&lt;strong&gt;1D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;The Work Group suggests limiting alcohol intake to no more than two standard drinks per day for men and no more than one standard drink per day for women. (&lt;strong&gt;2D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Blood Pressure Management in CKD ND Patients without Diabetes Mellitus&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The Work Group recommends that non-diabetic adults with CKD ND and urine albumin excretion &amp;lt;30 mg per 24 hours (or equivalent*) whose office BP is consistently &amp;gt;140 mm Hg systolic or &amp;gt;90 mm Hg diastolic be treated with BP-lowering drugs to maintain a BP that is consistently &amp;le;140 mm Hg systolic and &amp;le;90 mm Hg diastolic. (&lt;strong&gt;1B&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The Work Group suggests that non-diabetic adults with CKD ND and urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*) whose office BP is consistently &amp;gt;130 mm Hg systolic or &amp;gt;80 mm Hg diastolic be treated with BP-lowering drugs to maintain a BP that is consistently &amp;le;130 mm Hg systolic and &amp;le;80 mm Hg diastolic. (&lt;strong&gt;2D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The Work Group suggests that non-diabetic adults with CKD ND and urine albumin excretion &amp;gt;300 mg per 24 hours (or equivalent*) whose office BP is consistently &amp;gt;130 mm Hg systolic or &amp;gt;80 mm Hg diastolic be treated with BP-lowering drugs to maintain a BP that is consistently &amp;le;130 mm Hg systolic and &amp;le; 80 mm Hg diastolic. (&lt;strong&gt;2C&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The Work Group suggests that an angiotensin receptor blocker (ARB) or angiotensin converting enzyme inhibitor (ACE-I) be used in non-diabetic adults with CKD ND and urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*) in whom treatment with BP-lowering drugs is indicated. (&lt;strong&gt;2D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The Work Group recommends that an ARB or ACE-I be used in non-diabetic adults with CKD ND and urine albumin excretion &amp;gt;300 mg per 24 hours (or equivalent*) in whom treatment with BP-lowering drugs is indicated. (&lt;strong&gt;1B&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;*Approximate equivalents for albumin excretion rate per 24 hours&amp;mdash;expressed as protein excretion rate per 24 hours, albumin/creatinine ratio, protein/creatinine ratio, and protein reagent strip results&amp;mdash;are given in Table 1, Chapter 1 in the original guideline document.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Blood Pressure Management in CKD ND Patients with Diabetes Mellitus&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The Work Group recommends that adults with diabetes and CKD ND with urine albumin excretion &amp;lt;30 mg per 24 hours (or equivalent*) whose office BP is consistently &amp;gt;140 mm Hg systolic or &amp;gt;90 mm Hg diastolic be treated with BP-lowering drugs to maintain a BP that is consistently &amp;le;140 mm Hg systolic and &amp;le;90 mm Hg diastolic. (&lt;strong&gt;1B&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The Work Group suggests that adults with diabetes and CKD ND with urine albumin excretion &amp;gt;30 mg per 24 hours (or equivalent*) whose office BP is consistently &amp;gt;130 mm Hg systolic or &amp;gt;80 mm Hg diastolic be treated with BP-lowering drugs to maintain a BP that is consistently &amp;le;130 mm Hg systolic and &amp;le;80 mm Hg diastolic. (&lt;strong&gt;2D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The Work Group suggests that an ARB or ACE-I be used in adults with diabetes and CKD ND with urine albumin excretion of 30 to 300 mg per 24 hours (or equivalent*). (&lt;strong&gt;2D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The Work Group recommends that an ARB or ACE-I be used in adults with diabetes and CKD ND with urine albumin excretion &amp;gt;300 mg per 24 hours (or equivalent*). (&lt;strong&gt;1B&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;*Approximate equivalents for albumin excretion rate per 24 hours&amp;mdash;expressed as protein excretion rate per 24 hours, albumin/creatinine ratio, protein/creatinine ratio, and protein reagent strip results&amp;mdash;are given in Table 1, Chapter 1 in the original guideline document.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Blood Pressure Management in Kidney Transplant Recipients (Non&amp;ndash;dialysis-Dependent CKD of Any Stage with a Kidney Transplant [CKD T])&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The Work Group suggests that adult kidney transplant recipients whose office BP is consistently &amp;gt;130 mm Hg systolic or &amp;gt;80 mm Hg diastolic be treated to maintain a BP that is consistently &amp;le;130 mm Hg systolic and &amp;le;80 mm Hg diastolic, irrespective of the level of urine albumin excretion. (&lt;strong&gt;2D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In adult kidney transplant recipients, choose a BP-lowering agent after taking into account the time after transplantation, use of calcineurin inhibitors, presence or absence of persistent albuminuria, and other co morbid conditions. (&lt;strong&gt;Not Graded&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Blood Pressure Management in Children with CKD ND&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The Work Group recommends that in children with CKD ND, BP-lowering treatment is started when BP is consistently above the 90th percentile for age, sex, and height. (&lt;strong&gt;1C&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The Work Group suggests that in children with CKD ND (particularly those with proteinuria), BP is lowered to consistently achieve systolic and diastolic readings less than or equal to the 50th percentile for age, sex, and height, unless achieving these targets is limited by signs or symptoms of hypotension. (&lt;strong&gt;2D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The Work Group suggests that an ARB or ACE-I be used in children with CKD ND in whom treatment with BP-lowering drugs is indicated, irrespective of the level of proteinuria. (&lt;strong&gt;2D&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Blood Pressure Management in Elderly Persons with CKD ND&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Tailor BP treatment regimens in elderly patients with CKD ND by carefully considering age, co-morbidities and other therapies, with gradual escalation of treatment and close attention to adverse events related to BP treatment, including electrolyte disorders, acute deterioration in kidney function, orthostatic hypotension and drug side effects. (&lt;strong&gt;Not Graded&lt;/strong&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Final Grade for Overall Quality of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Final Grade for Overall Quality of Evidence&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Grade&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Quality of Evidence&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Meaning&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;A&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;High&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The Work Group is confident that the true effect lies close to that of the estimate of the effect.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;B&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;Moderate&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;C&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;Low&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The true effect may be substantially different from the estimate of the effect.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;D&lt;/td&gt;&#xD;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;Very Low&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The estimate of effect is very uncertain, and often will be far from the truth.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Nomenclature and Description for Grading Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Nomenclature and Description for Grading Recommendations&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; colspan=&quot;3&quot;&gt;Implications&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Grade&lt;sup&gt;a&lt;/sup&gt;&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Patients&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Clinicians&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Policy&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;strong&gt;Level 1&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;            'The Work Group recommends'&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Most people in your situation would want the recommended course of action and only a small proportion would not.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Most patients should receive the recommended course of action.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The recommendation can be evaluated as a candidate for developing a policy or a performance measure.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;strong&gt;Level 2&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;            'The Work Group suggests'&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The majority of people in your situation would want the recommended course of action, but many would not.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Different choices will be appropriate for different patients. Each patient needs help to arrive at a management decision consistent with her or his values and preferences.&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The recommendation is likely to require debate and involvement of stakeholders before policy can be determined.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;a&lt;/sup&gt;The additional category 'Not Graded' was used, typically, to provide guidance based on common sense or where the topic does not allow adequate application of evidence. The most common examples include recommendations regarding monitoring intervals, counseling, and referral to other clinical specialists. The ungraded recommendations are generally written as simple declarative statements, but are not meant to be interpreted as being stronger recommendations than Level 1 or 2 recommendations.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Appropriate management of blood pressure in patients with chronic kidney disease&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Potential adverse effects generic to treatment used to lower blood pressure include decreases in cerebral perfusion (contributing to dizziness, confusion and falls) and acute deterioration in kidney function&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Specific side effects of medications, of combinations of medications, and in specific populations are provided in Chapters 3-8, in summary tables and evidence profiles, and discussed in the rationale for each guideline statement in the original guideline document.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="430" OrdBy="800" Name="Contraindications"><Field FieldID="144" OrdBy="805" ID="431" Name="Contraindications" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Triamterene and amiloride are usually avoided in patients with chronic kidney disease (CKD) because of the risk of hyperkalemia. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It is wise to avoid dihydropyridine calcium channel blockers in CKD patients with already increased urinary albumin excretion, particularly if there is not concomitant use of an angiotensin converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Since clonidine can slow pulse rate, this drug should be avoided if bradycardia or heart block is present. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Use of the Clinical Practice Guideline&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This Clinical Practice Guideline document is based upon systematic literature searches last conducted in January 2011, supplemented with additional evidence through February 2012. It is designed to provide information and assist decision making. It is not intended to define a standard of care, and should not be construed as one, nor should it be interpreted as prescribing an exclusive course of management. Variations in practice will inevitably and appropriately occur when clinicians take into account the needs of individual patients, available resources, and limitations unique to an institution or type of practice. Every health-care professional making use of these recommendations is responsible for evaluating the appropriateness of applying them in any particular clinical situation. The recommendations for research contained within this document are general and do not imply a specific protocol.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Limitations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In children with chronic kidney disease (CKD), there is a dearth of randomized controlled trials; in fact, the recommendations in this chapter are largely based on a single trial, ESCAPE, which limits the quality of the evidence and the strength of the recommendations. The ESCAPE trial was performed in a predominantly Caucasian population. Therefore, the generalization of these findings to other populations is uncertain.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Living with Illness" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl. 2012 Dec;2(5):337-414. [453 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2004 May (revised 2012 Dec)" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="Kidney Disease: Improving Global Outcomes - Nonprofit Organization" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Kidney Disease: Improving Global Outcomes (KDIGO) is supported by the following consortium of sponsors: Abbott, Amgen, Bayer Schering Pharma, Belo Foundation, Bristol-Myers Squibb, Chugai Pharmaceutical, Coca-Cola Company, Dole Food Company, Fresenius Medical Care, Genzyme, Hoffmann-LaRoche, JC Penney, Kyowa Hakko Kirin, NATCO&amp;mdash;The Organization for Transplant Professionals, NKF-Board of Directors, Novartis, Pharmacosmos, PUMC Pharmaceutical, Robert and Jane Cizik Foundation, Shire, Takeda Pharmaceutical, Transwestern Commercial Services, Vifor Pharma, and Wyeth. No funding is accepted for the development or reporting of specific guidelines. All stakeholders could participate in open review.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Work Group Co-Chairs&lt;/em&gt;: Gavin J Becker, MD, FRACP, Royal Melbourne Hospital, Melbourne, Australia; David C Wheeler, MD, FRCP, University College London, London, United Kingdom&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Work Group Members&lt;/em&gt;: Dick de Zeeuw, MD, PhD, University Medical Center Groningen, Groningen, Netherlands; Toshiro Fujita, MD, University of Tokyo School of Medicine, Tokyo, Japan; Susan L Furth, MD, PhD, The Children's Hospital of Philadelphia, Philadelphia, PA, USA; Hallvard Holdaas, MD, PhD, Hospital Rikshospitalet, Oslo, Norway; Shanthi Mendis, MBBS, MD, FRCP, FACC, World Health Organization, Geneva, Switzerland; Suzanne Oparil, MD, University of Alabama, Birmingham, AL, USA; Vlado Perkovic, MBBS, FRACP, FASN, PhD, George Institute for International Health, Sydney, Australia; Cibele Isaac Saad Rodrigues, MD, PhD, Catholic University of S&amp;atilde;o Paulo, S&amp;atilde;o Paulo, Brazil; Mark J Sarnak, MD, MS, Tufts Medical Center, Boston, MA, USA; Guntram Schernthaner, MD, Rudolfstiftung Hospital, Vienna, Austria; Charles R V Tomson, DM, FRCP, Southmead Hospital, Bristol, United Kingdom; Carmine Zoccali, MD, CNR-IBIM Clinical Research Unit, Ospedali Riuniti, Reggio Calabria, Italy&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Evidence Review Team Members&lt;/em&gt;: Tufts Center for Kidney Disease Guideline Development and Implementation, Tufts Medical Center, Boston, MA, USA: Katrin Uhlig, MD, MS, Project Director, Director, Guideline Development; Ashish Upadhyay, MD, Assistant Project Director; Amy Earley, BS, Project Coordinator; Shana Haynes, MS, DHSc, Research Assistant; Jenny Lamont, MS, Project Manager&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;In addition, support and supervision were provided by&lt;/em&gt;: Ethan M Balk, MD, MPH, Program Director, Evidence Based Medicine&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Kidney Disease: Improving Global Outcomes (KDIGO) makes every effort to avoid any actual or reasonably perceived conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the Work Group. All members of the Work Group are required to complete, sign, and submit a disclosure and attestation form showing all such relationships that might be perceived or actual conflicts of interest. This document is updated annually and information is adjusted accordingly. All reported information is published in its entirety at the end of the original guideline document in the Work Group members' Biographic and Disclosure Information section, and is kept on file at the National Kidney Foundation (NKF), Managing Agent for KDIGO.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004 May;43(5 Suppl 1):S1-290.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies of the guideline: Available from the &lt;a href=&quot;http://www.kdigo.org/clinical_practice_guidelines/bp.php&quot; title=&quot;Kidney Disease: Improving Global Outcomes (KDIGO) Web site&quot;&gt;Kidney Disease: Improving Global Outcomes (KDIGO) Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Appendices 1-2. New York: Kidney Disease: Improving Global Outcomes; 2012 Dec. 12 p. Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO_BP_GL_Appendices_1_and_2_Dec_2012.pdf&quot; title=&quot;Kidney Disease: Improving Global Outcomes (KDIGO) Web site&quot;&gt;Kidney Disease: Improving Global Outcomes (KDIGO) Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Online supplemental tables. New York: Kidney Disease: Improving Global Outcomes; 2012 Dec. 127 p. Electronic copies: Available in PDF from the &lt;a href=&quot;http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO_BP_GL_Suppl_Table_Dec_2012.pdf&quot; title=&quot;Kidney Disease: Improving Global Outcomes (KDIGO) Web site&quot;&gt;KDIGO Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Methods for development of KDIGO clinical practice guidelines. Electronic copies: Available from the &lt;a href=&quot;http://kdigo.org/home/guidelines/development/&quot; title=&quot;Kidney Disease: Improving Global Outcomes (KDIGO) Web site&quot;&gt;KDIGO Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI on February 23, 2005. This NGC summary was updated by ECRI Institute on April 1, 2013.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Copyright &amp;copy; 2012 by KDIGO. All rights reserved.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Single photocopies may be made for personal use as allowed by national copyright laws. Special rates are available for educational institutions that wish to make photocopies for non-profit educational use. No part of this publication may be reproduced, amended, or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without explicit permission in writing from KDIGO. Details on how to seek permission for reproduction or translation, and further information about KDIGO's permissions policies can be obtained by contacting Anita Viliusis, KDIGO Permissions Manager, at &lt;a href=&quot;mailto:anita.viliusis@kidney.org&quot;&gt;anita.viliusis@kidney.org&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
